Muscle Invasive Bladder Cancer Overview
Learn About Muscle Invasive Bladder Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
MD Anderson
Ashish Kamat is an Urologist in Houston, Texas. Dr. Kamat and is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.
Temple Faculty Practice Plan Inc
Elizabeth Plimack is an Oncologist and a Transplant Surgeon in Philadelphia, Pennsylvania. Dr. Plimack and is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy.
Temple Faculty Practice Plan Inc
Marc Smaldone is a General Surgeon and an Urologist in Philadelphia, Pennsylvania. Dr. Smaldone and is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Nephrectomy, and Cystectomy.
Summary: This phase II/III trial examines whether patients who have undergone surgical removal of bladder, but require an additional treatment called immunotherapy to help prevent their bladder cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (...
Summary: This is a phase II, single arm, Simon two-stage design, trial, enrolling patients with cisplatin ineligible MIBC and/or those patients who decline cisplatin based NAC. Assess rates of pathologic downstaging and quality of life in MIBC cisplatin-ineligible/declined patients when IVC is added to gemcitabine-carboplatin NAC.